Xenon Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
Xenon Pharmaceuticals Il CEO è Ian Mortimer, nominato in Mar2018, e ha un mandato di 6.67 anni. la retribuzione annua totale è $ 10.12M, composta da 6.6% di stipendio e 93.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.06% delle azioni della società, per un valore di $ 1.78M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 3.7 anni.
Informazioni chiave
Ian Mortimer
Amministratore delegato
US$10.1m
Compenso totale
| Percentuale dello stipendio del CEO | 6.6% |
| Mandato del CEO | 6.7yrs |
| Proprietà del CEO | 0.06% |
| Durata media del management | 4.3yrs |
| Durata media del Consiglio di amministrazione | 3.7yrs |
Aggiornamenti recenti sulla gestione
We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29
Recent updates
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 20Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?
Aug 09Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Jul 05We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$213m |
| Jun 30 2024 | n/a | n/a | -US$199m |
| Mar 31 2024 | n/a | n/a | -US$189m |
| Dec 31 2023 | US$10m | US$666k | -US$182m |
| Sep 30 2023 | n/a | n/a | -US$176m |
| Jun 30 2023 | n/a | n/a | -US$165m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$9m | US$595k | -US$126m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$91m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$4m | US$524k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$59m |
| Mar 31 2021 | n/a | n/a | -US$37m |
| Dec 31 2020 | US$2m | US$462k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$2m | US$421k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$42m |
| Dec 31 2018 | US$923k | US$342k | -US$34m |
| Sep 30 2018 | n/a | n/a | -US$34m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$945k | US$312k | -US$31m |
Compensazione vs Mercato: La retribuzione totale di Ian ($USD 10.12M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.57M ).
Compensazione vs guadagni: La retribuzione di Ian è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Ian Mortimer (48 yo)
6.7yrs
Mandato
US$10,117,829
Compensazione
Mr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021. He has been an Independent Director at Perimeter Medical Imag...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 6.7yrs | US$10.12m | 0.060% $ 1.8m | |
| Chief Financial Officer | 3.4yrs | US$3.52m | 0% $ 0 | |
| Executive Vice President of Strategy & Innovation | no data | US$2.37m | Nessun dato | |
| Chief Commercial Officer | 4.3yrs | US$2.76m | 0.0053% $ 156.4k | |
| Chief Medical Officer | 3.3yrs | US$3.58m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | 2yrs | US$3.55m | Nessun dato | |
| Executive Vice President of Human Resources | 5.2yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Drug Discovery | 8.8yrs | US$545.00k | Nessun dato | |
| Executive Vice President of R&D Operations | 4.3yrs | Nessun dato | Nessun dato |
4.3yrs
Durata media
54.5yo
Età media
Gestione esperta: Il team dirigenziale di XENE è considerato esperto (durata media dell'incarico 4.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 3.4yrs | US$10.12m | 0.060% $ 1.8m | |
| Independent Director | 1.3yrs | US$770.91k | Nessun dato | |
| Independent Director | 20.8yrs | US$560.09k | 0.038% $ 1.1m | |
| Independent Director | 4yrs | US$559.58k | Nessun dato | |
| Independent Director | 9.5yrs | US$561.42k | 0.0026% $ 78.2k | |
| Independent Chairman | 8.2yrs | US$588.37k | 0.033% $ 976.8k | |
| Independent Director | 1.3yrs | US$770.91k | Nessun dato | |
| Independent Director | 3.4yrs | US$548.57k | Nessun dato |
3.7yrs
Durata media
61.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di XENE sono considerati esperti (durata media dell'incarico 3.7 anni).